drugset / Trial / NCT02841774
High Intensity Lipid Lowering Following Acute Coronary Syndromes for Persons Living With HIV
RandomizedParallel-groupOpen-labelTreatment
Summary
HILLCLIMBER is a randomized, controlled, open-label phase II trial of moderate dose statin therapy (pravastatin 40mg daily) versus high-dose statin therapy (rosuvastatin 20-40mg daily) in HIV-infected persons taking antiretroviral therapy (ART) who have coronary heart disease (CHD).
Timeline
- Start
- 2016-11
- Primary completion
- 2021-06
- Completion
- 2021-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Pravastatin | Small molecule | 40 mg | — |
| Subject | Rosuvastatin | Small molecule | 20 mg | — |
| Subject | Rosuvastatin | Small molecule | 40 mg | — |